Dhanuka Agritech Q4 Net Profit Rises 29.5%; Board Approves Buyback

Dhanuka Agritech announced its audited financial results for the quarter and year ended March 31, 2026. The company posted a net profit of ₹287.23 crore for the full year, while profit after tax for Q4 FY26 stood at ₹97.77 crore, marking a 29.50% increase from the previous year. Revenue from operations for Q4 FY26 was ₹483.34 crore, compared to ₹442.02 crore in Q4 FY25. EBITDA for the quarter improved to ₹124.89 crore, with the EBITDA margin expanding to 25.84% from 24.83% in the same period last year.

Financial Performance

The following table summarizes the key financial metrics for the quarter and full year (₹ in Crores):

Particulars: Q4 FY26 Q4 FY25 YoY % FY26 FY25 YoY % Revenue from Operations 483.34 442.02 9.35% 2,019.79 2,035.15 (0.75%) EBITDA 124.89 109.75 13.79% 403.48 416.61 (3.15%) EBITDA Margin 25.84% 24.83% +101 bps — — — Net Profit 97.77 75.50 29.50% 287.23 296.96 (3.28%) Basic EPS (₹) 21.69 16.74 29.57% 63.72 65.55 (2.79%)

The company noted that Q4 is seasonally a softer quarter, with the Rabi season impacted by unfavorable climatic conditions in certain regions.

FY27 Outlook and Guidance

For FY 2026-27, Dhanuka Agritech has provided guidance for low double-digit growth in revenue from operations, compared to 9% revenue growth recorded in FY26. The company expects price increases to outpace volume growth by approximately 2%. Additionally, an EBITDA margin decline of approximately 100 basis points is anticipated for the year ahead.

Operational Highlights

Dhanuka Agritech operates in a single reportable segment, Agro Chemicals. The revenue mix for Q4 FY26 was well-diversified across geographies and segments. North and South regions contributed 32% and 33% respectively, while Insecticides and Herbicides accounted for 41% and 31% of the total revenue. New molecules contributed 13.93% to the total revenue in FY26.

Corporate Actions

The Board of Directors approved a buyback of up to 5,00,000 fully paid-up equity shares, representing 1.11% of the paid-up capital, at a price of ₹1,400 per share. The aggregate offer size is up to ₹70 crore, to be conducted via the Tender Offer route. The record date for the buyback has been confirmed as Friday, May 29, 2026.

Additionally, the Board recommended a final dividend of 100%, or ₹2 per equity share of face value ₹2 each, for FY26. This will absorb approximately ₹9.02 crore and is subject to shareholder approval at the 41st Annual General Meeting scheduled for August 3, 2026. The record date for dividend eligibility is Friday, July 17, 2026.

Employee Benefits and Expansion

The Board approved the introduction of the Dhanuka Employee Stock Option Plan 2026, covering up to 50,000 stock options representing 0.11% of the equity share capital. Furthermore, the company approved the establishment of wholly owned subsidiaries in Brazil and a European country to support international expansion and brand registration.

Commenting on the performance, Mr. M.K. Dhanuka, Chairman, Dhanuka Agritech Ltd., stated that the company delivered healthy growth supported by improved demand and product portfolio strength. He noted that while the monsoon outlook remains below normal, the agriculture sector shows resilience supported by better farm practices and technology adoption.

dhanuka agritech has announced the superannuation of Mr. K.B. Kejariwal from the position of President – Production. The senior management personnel retired effective from the close of business hours on March 31, 2026, upon attaining the age of superannuation.

Board Acknowledges Contributions

The Board of Directors of Dhanuka Agritech convened a meeting on May 19, 2026, to take the superannuation on record. During the meeting, the Board placed on record its appreciation for the valuable contributions made by Mr. K.B. Kejriwal towards the growth of the company during his tenure. The requisite intimation regarding this development was submitted to the stock exchanges within 30 minutes of the conclusion of the Board Meeting.

Details of the Change

The company provided specific details regarding the change in its senior management personnel as required under Regulation 30 of the Listing Regulations. The reason for the change was cited as superannuation, and the effective date was confirmed as the end of business hours on March 31, 2026.

Particulars Details Name Mr. K.B. Kejariwal Position President – Production Reason for Change Superannuation Effective Date March 31, 2026

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.